Drug Design, Development and Therapy (Mar 2022)
Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies
Abstract
Xuefei Ding,1,* Yijun Hu,2,3,* Honghua Yu,2 Qiuming Li1 1Department of Ophtalmology, Henan Eye Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Department of Ophthalmology, Guangdong Eye Institute, Guangdong Provincial People’ s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China; 3Refractive Surgery Center, Aier Institute of Refractive Surgery, Guangzhou Aier Eye Hospital, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qiuming Li, Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe Road, Zhengzhou, 450052, People’s Republic of China, Tel +86 15837188476, Email [email protected] Honghua Yu, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, No. 106, Zhongshan Second Road, Guangzhou, 510080, People’s Republic of China, Email [email protected]: This study aimed to assess the short-term changes of macular microstructures following anti-VEGF and anti-inflammatory therapies in patients with macular edema secondary to retinal vein occlusion (RVO-ME).Patients and Methods: In this retrospective study, 70 eyes of 70 patients with RVO-ME were divided into the anti-VEGF (Group A, 35 eyes) and anti-inflammatory (Group B, 35 eyes) treatment groups. All patients underwent best-corrected visual acuity (BCVA) assessment, intraocular pressure (IOP) assessment, slit lamp, fundus fluorescein angiography (FA), scanning laser ophthalmoscopy (SLO), and spectral-domain optical coherence tomography (SD-OCT). Group A received intravitreal injection of 0.05 mL anti-VEGF antibodies (Lucentis® or Aflibercept®) monthly for 3 consecutive months, while Group B received 0.7 mg dexamethasone (Ozurdex®) single intravitreal injection. BCVA and SD-OCT biomarkers were recorded at baseline and 3 months after the first injection. Changes of BCVA and SD-OCT biomarkers following these treatments were compared between the two groups.Results: BCVA and SD-OCT biomarkers, except choroidal thickness, in both groups were significantly improved after treatment (all P 0.05).Conclusion: Anti-VEGF and anti-inflammatory therapies are both effective in RVO-ME, with improvement in BCVA and SD-OCT biomarkers. Anti-inflammatory therapy may be more effective than anti-VEGF therapy in SRD and HRD resolution.Keywords: macular edema, SD-OCT, biomarkers, anti-VEGF therapy, anti-inflammatory therapy
